Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Novelix Pharmaceuticals's Pretax Margin % or its related term are showing as below:
BOM:536565'
s Pretax Margin % Range Over the Past 10 Years
Min: -185.7 Med: -1.62 Max: 2.57
Current: 2.57
BOM:536565's Pretax Margin % is ranked better than 53.85% of 117
companies
in the Medical Distribution industry
Industry Median: 2.31
vs BOM:536565: 2.57
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Novelix Pharmaceuticals Pretax Margin % Related Terms
Novelix Pharmaceuticals Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:536565 vs MCK, CAH, COR: Pretax Margin % Comparison
For the Medical Distribution subindustry, Novelix Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novelix Pharmaceuticals Pretax Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Novelix Pharmaceuticals's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Novelix Pharmaceuticals's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novelix Pharmaceuticals (BOM:536565) has a Pretax Margin % of 4.89% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Novelix Pharmaceuticals and its competitors. According to the industry distribution chart, Novelix Pharmaceuticals ranks #54 out of 117 companies in the Medical Distribution industry, placing it in the top 46.2%.
Is Novelix Pharmaceuticals' Pretax Margin % too high?
Novelix Pharmaceuticals' current Pretax Margin % is 4.89%. The Medical Distribution industry median Pretax Margin % is 2.31. Novelix Pharmaceuticals' value of 4.89% is 111.7% above this industry median. Based on the distribution chart, Novelix Pharmaceuticals ranks #54 out of 117 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Novelix Pharmaceuticals has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Novelix Pharmaceuticals' Pretax Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Novelix Pharmaceuticals ranks #54 out of 117 companies for Pretax Margin %. This puts Novelix Pharmaceuticals in the upper half of its industry. The industry median Pretax Margin % is 2.31. Novelix Pharmaceuticals' value of 4.89% is 111.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Distribution company?
The median Pretax Margin % among Medical Distribution companies is 2.31, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novelix Pharmaceuticals's current Pretax Margin % of 4.89% is 111.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Novelix Pharmaceuticals and its competitors. For the Medical Distribution industry, the median Pretax Margin % is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novelix Pharmaceuticals's current Pretax Margin % is 4.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novelix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Novelix Pharmaceuticals (BOM:536565) is currently considered Possible Value Trap. The stock's GF Value™ is ₹145.37, compared to a current price of ₹66.42 — trading 54.3% below its estimated fair value. The current Pretax Margin % is 4.89% and 111.7% above the Medical Distribution industry median of 2.31. Novelix Pharmaceuticals' overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Novelix Pharmaceuticals (BOM:536565), the current Pretax Margin % is 4.89% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novelix Pharmaceuticals (BOM:536565) Overvalued in 2026?
Based on GuruFocus' analysis, Novelix Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹66.42 is trading 54.3% below its estimated GF Value™ of ₹145.37.
GuruFocus considers Novelix Pharmaceuticals to be Possible Value Trap.
Key valuation signals for BOM:536565:
Pretax Margin %: 4.89%
GF Value™: ₹145.37 vs. price of ₹66.42 (54.3% below fair value)
Industry Position: 111.7% above the Medical Distribution median (#54 of 117)
No single metric tells the full story. See the BOM:536565 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novelix Pharmaceuticals Ltd is into the business of Trading of Pharmaceuticals and related products and is into the business of trading of shares and securities. The company generates majaority of its revenue from the Pharmaceuticals business.
62GF Score
Get the complete analysis for BOM:536565
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:536565 has been successfully added to your 
